Abstract

Thirty-six out of sixty-two cases of myelomatosis have been treated with melphalan.

Platelet counts were used as a guide to dosage early in the course of treatment, after which a more empirical dosage (0·15 mg/kg/day) was used in 1-week courses given every 12 weeks.

Rapid deterioration and death occur in a small number of patients whatever therapy is given.

In the group treated with melphalan the median survival time was 25 months, longer than in those treated with radiotherapy or other chemotherapeutic agents.